Cargando…

Evaluation of Predisposing Metabolic Risk Factors for Portopulmonary Hypertension in Patients with NASH Cirrhosis

PURPOSE: Metabolic parameters are important for the development of portopulmonary hypertension (PoPH) during nonalcoholic steatohepatitis (NASH)-associated cirrhosis. This study evaluated patients with NASH-associated cirrhosis to determine metabolic risk factors for portopulmonary hypertension. PAT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Türker, Fatih, Sahın, Tolga, Oral, Alihan, Koçak, Erdem, Çavuşoğlu Türker, Betül, Niğdelioğlu, Adil, Esra Ataoğlu, Hayriye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800581/ https://www.ncbi.nlm.nih.gov/pubmed/35115812 http://dx.doi.org/10.2147/IJGM.S339474

Ejemplares similares

Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
por: Türker, Fatih, et al.
Publicado: (2021)

Can hypothyroidism be a protective factor for hepatocellular carcinoma in cirrhosis?
por: Sahin, Tolga, et al.
Publicado: (2020)

Relationship between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients
por: Oral, Alihan, et al.
Publicado: (2019)

Evaluation of Plateletcrit and Platelet Distribution Width in Patients with Non-Alcoholic Fatty Liver Disease: A Retrospective Chart Review Study
por: Oral, Alihan, et al.
Publicado: (2019)

Serum albumin and FT3/FT4 ratio as additional co-morbidity parameters to predict mortality as a new approach: The Haseki Scoring Index (updated Charlson Comorbidity Index)
por: Cavusoglu Turker, Betul, et al.
Publicado: (2022)

Evaluation of the Charlson Comorbidity Index and Laboratory Parameters as Independent Early Mortality Predictors in Covid 19 Patients
por: Cavuşoğlu Türker, Betül, et al.
Publicado: (2022)

FT3/FT4 ratio predicts non-alcoholic fatty liver disease independent of metabolic parameters in patients with euthyroidism and hypothyroidism
por: Gökmen, Fatma Yahyaoğlu, et al.
Publicado: (2016)

Factor 5 and Factor 2 heterozygous positivity and complications in living donor liver transplant donors
por: Anilir, Ender, et al.
Publicado: (2023)

Incidental combined hepatocellular-cholangiocarcinoma in liver transplant patients: Does it have a worse prognosis?
por: Anilir, Ender, et al.
Publicado: (2023)

Systemic Immune-Inflammation and Systemic Inflammation Response Indices are Predictive Markers of Mortality in Inpatients Internal Medicine Services
por: Çavuşoğlu Türker, Betül, et al.
Publicado: (2023)

The comparison of pancreatic and hepatic steatosis in healthy liver donor candidates
por: Koyuncu Sokmen, Bedriye, et al.
Publicado: (2021)

Portopulmonary hypertension
por: Saleemi, Sarfraz
Publicado: (2010)

Prevalence and Clinical Features of Portopulmonary Hypertension in Patients With Hepatic Cirrhosis: An Echocardiographic Study
por: Gupta, Anany, et al.
Publicado: (2022)

Prognostic role of ABO blood group and Rhesus factor in cirrhotic patients with hepatocellular carcinoma
por: Oral, Alihan, et al.
Publicado: (2019)

Portopulmonary Hypertension: An Updated Review
por: Jasso-Baltazar, Erick A., et al.
Publicado: (2023)

Portopulmonary Hypertension: From Bench to Bedside
por: Thomas, Christopher, et al.
Publicado: (2020)

Causes and Circumstances of Death in Portopulmonary Hypertension
por: Sahay, Sandeep, et al.
Publicado: (2021)

Association between Body Composition and the Risk of Portopulmonary Hypertension Assessed by Computed Tomography in Patients with Liver Cirrhosis
por: Miwa, Takao, et al.
Publicado: (2023)

Portopulmonary hypertension: Success with combined medical treatment
por: Hernández, María, et al.
Publicado: (2023)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Portopulmonary hypertension
por: Saleemi, Sarfraz, et al.
Publicado: (2014)

The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan
por: Takahashi, Yukiko, et al.
Publicado: (2021)

Current clinical understanding and effectiveness of portopulmonary hypertension treatment
por: Tamura, Yuichi, et al.
Publicado: (2023)

Current Therapy and Liver Transplantation for Portopulmonary Hypertension in Japan
por: Tokushige, Katsutoshi, et al.
Publicado: (2023)

Portopulmonary hypertension caused by portal hypertension that is complicated by central diabetes insipidus
por: Zhao, Tingting, et al.
Publicado: (2020)

The early outcomes of candidates with portopulmonary hypertension after liver transplantation
por: Huang, Bingsong, et al.
Publicado: (2018)

Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients
por: Li, Jian, et al.
Publicado: (2018)

BMP9 Morphs into a Potential Player in Portopulmonary Hypertension
por: Toshner, Mark
Publicado: (2019)

Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes
por: DuBrock, Hilary M., et al.
Publicado: (2019)

Possible use of pulmonary artery stiffness in screening for portopulmonary hypertension
por: Wessels, Jeroen N., et al.
Publicado: (2022)

The Different Effects of Direct Bilirubin on Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension
por: Li, Yuan, et al.
Publicado: (2022)

Situs inversus totalis and secondary biliary cirrhosis: a case report
por: Sökmen, Hacı Mehmet, et al.
Publicado: (2011)

Portopulmonary hypertension in cirrhotic patients: Prevalence, clinical features and risk factors
por: CHEN, HUI-SONG, et al.
Publicado: (2013)

Venous outflow obstruction and portopulmonary hypertension after orthotopic liver transplantation
por: Aguirre-Avalos, Guadalupe, et al.
Publicado: (2013)

Left main coronary artery compression in a patient with portopulmonary hypertension
por: de Araújo, Iara Teixeira, et al.
Publicado: (2018)

Living donor liver transplantation in a patient with severe portopulmonary hypertension
por: Singh, Shweta A, et al.
Publicado: (2020)

Sarcoidosis-induced pericarditis in a patient with portopulmonary hypertension: a case report
por: Giouleme, Olga, et al.
Publicado: (2009)

Natural killer cell-mediated immune deficiency or compromise in patients with portopulmonary hypertension
por: Chen, Huisong, et al.
Publicado: (2014)

Portopulmonary hypertension in children: a rare but potentially lethal and under-recognized disease
por: Tingo, Jennifer, et al.
Publicado: (2017)

Management of acute subdural hematoma in a patient with portopulmonary hypertension on prostanoid therapy
por: Rammo, Richard, et al.
Publicado: (2017)

Liver transplantation for severe portopulmonary hypertension: A case report and literature review
por: Chen, Xiao-Jie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s8o8dc0juf7go0ieoijilfae9h